Wei Tan

Senior Business and Development Director at Kanglin Biotec (Hangzhou) Co., Ltd.

Presenter

Kanglin biotechnology is a China rooted biotec committed to develop BIC and FIC gene therapies. Built upon its excellent innovation capabilities, Kanglin has successfully established three core technology platforms - adeno-associated virus (AAV) vector, lentivirus (LV) vector and hematopoietic stem cell (iHSC). With these platforms, Kanglin has formed a portfolio of differentiated pipelines to treat β-thalassaemia, haemophilia, Parkinson's disease and etc: KL003, a gene therapy drug for β-thalassaemia/sickle cell anaemia, has successfully cured 17 patients in an investigator-initiated clinical trial (IIT). Those clinical data has shown better efficacy and safety, compared to approved products in those indications. KL003 has received IND approval in China and is currently in a registrational Ph.I/II trial, planning to enroll 41 patients. Meanwhile, KL003 has also been granted RPDD and ODD designations by FDA. KL001, a non-hepato-targeted AAV vector, has also been developed to treat Hemophilia B. Preliminary data of two patients from an IIT has shown very promising efficacy (FIX activity and APTT) five weeks after treatment.  KL002, a one time delivery of three genes to synthesize dompamine on situ. Early rat and mice data has shown superior data vs. competitors. IIT of KL002 has initiated in Q2. 2024 Besides the efficacy and safety, Kanglin is also addressing one of the important challenges of gene therapies: affordability. By systemzatically opitimizng the manufacturing process, Kanglin has drastically reduced the cost for KL002 and KL003. This would enhance the cost efificiency for genetherapies and their accessibility.